Seminars in Nuclear Medicine
Volume 37, Issue 1 , Pages 17-28 , January 2007

Synergistic Value of Single-Photon Emission Computed Tomography/Computed Tomography Fusion to Radioimmunoscintigraphic Imaging of Prostate Cancer

  • D. Bruce Sodee, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to D. Bruce Sodee, MD, Department of Radiology, Division of Nuclear Medicine, University Hospitals of Cleveland and Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106.
    • ,
  • Adriane E. Sodee, BA
    • ,
  • George Bakale, PhD

References 

  1. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: Current applications and future directions. Radiology. 2006;238:405–422
  2. Townsend DW, Cherry SR. Combining anatomy and function: the path to true image fusion. Eur Radiology. 2001;11:1968–1974
  3. Strauss HW. Nuclear medicine 2020. Q J Nucl Med Mol Imaging. 2006;50:1–3
  4. Jana S, Blaufox MD. Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med. 2006;36:51–72
  5. Babaian RJ, Sayer J, Podoloff DA, et al. Radioimmunoscintigraphy of pelvic lymph nodes with 111-indium-labeled monoclonal antibody CYT-356. J Urol. 1994;152:1952–1955
  6. Manyak MJ, Hinkle GH, Olsen JO, et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology. 1999;54:1058–1063
  7. Han M, Partin AW. Current Applications of the indium-111 capromab pendetide scan (ProstaScint scan, Cyt-356). Rev Urol. 2001;3:165–171
  8. Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol. 2001;7:27–37
  9. Sodee DB, Ellis RJ, Samuels MA, et al. Prostate cancer and prostate bed SPECT imaging with ProstaScint: semi-quantitative correlation with prostatic biopsy results. Prostate. 1998;37:140–148
  10. Nelson AD, Sodee DB, Lee Z, et al. Reconstruction and analysis methods for diagnostic ProstaScint image evaluation. Electromedica. 2000;68:45–48
  11. Faulhaber PF, Mehta L, Echt EA, et al. Perfecting the practice of FDG-PET: pitfalls and artifacts. In:  Freeman LM editors. Nuclear Medicine Annual 2002. New York: Lippincott, Williams & Wilkins; 2002;p. 149–213
  12. Hofer C, Laubenbacher C, Block T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol. 1999;36:31–35
  13. Leisure GP, Vesselle HJ, Faulhaber PF, et al. Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. J Nucl Med Technol. 1997;25:115–119
  14. de Jong IJ, Pruim J, Elsinga PH, et al. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol. 2002;42:18–23
  15. DeGrado TR, Coleman RE, Wang SY. Synthesis and evaluation of F-18-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res. 2001;61:110–117
  16. Kotzerke J, Volkmer BG, Neumaier B, et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med. 2002;29:1380–1384
  17. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16β-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366–373
  18. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 2006;57:99–118
  19. Reinartz P, Wieres FJ, Schneider W, et al. Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT?. Eur J Nucl Med Mol Imaging. 2004;31:1456–1461
  20. Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostate-specific membrane antigen a multifunctional protein?. Am J Physiol Cell Physiol. 2005;288:C975–C981
  21. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal-antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic-cancer patients. Anticancer Res. 1987;7:927–936
  22. Wright GE, Haley C, Beckett ML, et al. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol Oncol. 1995;1:18–28
  23. Fair WR, Israeli RS, Heston WD. Prostate-specific membrane antigen. Prostate. 1997;32:140–148
  24. Loric S, Dumas F, Eschwege P, et al. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin Chem. 1995;41:1698–1704
  25. Schmidt B, Anastasiadis AG, Seifert HH, et al. Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade. Anticancer Res. 2003;23:3991–3999
  26. ProstaScint capromab pendetide package insert. Princeton, NJ: Cytogen Corp; 1997;
  27. Sodee DB, Nelson AD, Faulhaber PF, et al. Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005;3:230–238
  28. Keidar Z, Israel O, Krausz Y. SPECT/CT in tumor imaging: technical aspects and clinical applications. Semin Nucl Med. 2003;33:205–218
  29. Wagner HN. Highlights 2000 Lecture—The internet: The road to smart nuclear medicine. J Nucl Med. 2000;41:9N–34N
  30. Wagner HN. SNM Highlight Lecture—Horizons near and far: Molecular focus, global involvement. J Nucl Med. 2005;46:11N–44N
  31. Townsend DW, Beyer T, Blodgett TM. PET/CT scanners: a hardware approach to image fusion. Sem Nucl Med. 2003;33:193–204
  32. Lee Z, Sodee DB, Duerk JL, et al. Automatic registration of SPECT-MRI in the pelvis. J Nucl Med. 2000;41:59P;(abstr)
  33. Sodee DB, Malguria N, Faulhaber P, et al. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer (The ProstaScint Imaging Centers). Urology. 2000;56:988–993
  34. Sodee DB, Faulhaber PF, Nelson AD, et al: Optimizing prostate cancer imaging. Medscape online. Available at: http://www.medscape.com/viewarticle/408705. Accessed August 6, 2006
  35. Sodee DB. Prostate cancer imaging 2002: Correlation with prostate cancer histology. 2001;Presented at AACR Conference: New Discoveries in Prostate Cancer Biology and Treatment, Naples, FL, December 5-9
  36. Sodee DB. Bone, PET and ProstaScint scans. 2003;Presented at the 13th Annual Prostate Cancer Update, Vail, CO, February 19-23
  37. Sodee DB. Prostate cancer imaging: Bone, PET and ProstaScint imaging. 2002;Presented at Prostate Cancer 2002: New Perspectives, Baltimore, MD, September 25-29
  38. Sodee DB. Molecular imaging with nuclear medicine: Histological confirmation of SPECT images fused with CT/MRI. 2004;Presented at Think Tank: Molecular Imaging of Prostate Cancer, Washington, DC, February 2-4
  39. Sodee DB. SPECT images fused with CT/MRI. 2005;Presented at National Conference on Prostate Cancer 2005, Washington, DC, June 16-19
  40. Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 2003;21:1715–1721
  41. Sodee DB, Faulhaber PF, Nelson AD, et al. The prognostic significance of indium-111-capromab pendetide. J Clin Oncol. 2004;22:379–380
  42. Sodee DB, Nelson AD, Faulhaber PF, et al. Radioimmunoscintigraphy for imaging prostate cancer. In:  Kirby RS,  Partin AW,  Feneley M,  Parsons JK editor. Prostate Cancer: Principles and Practice. London: Taylor & Francis; 2006;p. 519–529
  43. Blend MJ, Sodee DB. ProstaScint: an update. In:  Freeman LM editors. Nuclear Medicine Annual 2001. New York, NY: Lippincott, Williams, & Wilkins; 2001;p. 109–138
  44. Schettino CJ, Kramer EL, Noz ME, et al. Impact of fusion of Indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR Am J Roentgenol. 2004;183:519–524
  45. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 1999;162:1322–1328
  46. DeWyngaert JK, Noz ME, Ellerin B, et al. Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning. Int J Radiat Oncol Biol Phys. 2004;60:654–662
  47. Kahn D, Williams RD, Seldin DW, et al. Radioimmunoscintigraphy with 111-indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol. 1994;152:1490–1495
  48. Kahn D, Williams RD, Hasemann MK, et al. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol. 1998;16:284–289
  49. Levesque PE, Nieh PT, Zinman LN, et al. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology. 1998;51:978–984
  50. Murphy GP, Elgamal A-AA, Troychak MJ, et al. Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy. Prostate. 2000;42:315–317
  51. Ellis RJ, Sodee DB, Spirnak JP, et al. Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;48:683–687
  52. Ellis RJ, Vertocnik A, Kim E, et al. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. Int J Radiat Oncol Biol Phys. 2003;57:362–370
  53. Ellis RJ, Kim EY, Zhou H, et al. Seven-year biochemical disease-free survival rates following permanent prostate brachytherapy with dose escalation to biological tumor volumes (BTVs) identified with SPECT/CT image fusion. 2005;Presented at the 26th American Brachytherapy Society Annual Meeting, San Francisco, CA, June 1-3
  54. Pinkawa M, Asadpour B, Gagel B, et al. Prostate position variability and dose–volume histograms in radiotherapy for prostate cancer with full and empty bladder. Int J Radiat Oncol Biol Phys. 2006;64:856–861
  55. Chi Y, Liang J, Yan D. A material sensitivity study on the accuracy of deformable organ registration using linear biomechanical models. Med Phys. 2006;33:421–433
  56. Carl J, Lund B, Larson EH, et al. Feasibility study using a Ni-TI stent and electronic portal imaging to localize the prostate during radiotherapy. Radiother Oncol. 2006;78:199–206
  57. Ellis RJ, Kim , Vertocnik A, et al. Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma. Brachytherapy. 2003;2:215–222
  58. Ellis RJ, Kim E, Zou H, et al. Radioimmunoguided transperineal brachytherapy with or without external beam radiotherapy for hormone-naïve patients with prostate adenocarcinoma. 2003;Presented at the 24th Annual Meeting of the American Brachytherapy Society, New York, NY, May 8-10
  59. Jani AB, Spelbring D, Hamilton R, et al. Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy. J Nucl Med. 2004;45:238–246
  60. Jani AB, Blend MJ, Hamilton R, et al. Influence of radioimmunoscintigraphy on post-prostatectomy radiotherapy treatment decision-making. J Nucl Med. 2004;45:571–578
  61. Jani AB, Blend MJ, Hamilton R, et al. Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med. 2004;45:1315–1322
  62. Kahn D, Austin JC, Maguire RT, et al. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother Radiopharm. 1999;14:99–111
  63. Troyer JK, Feng Q, Beckett ML, et al. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol. 1995;1:29–37
  64. Troyer JK, Beckett ML, Wright GL. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate. 1997;7:232–242
  65. Barren RJ, Holmes EH, Boynton AL, et al. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate. 1997;30:65–68
  66. Ren JQ, Chen ZQ, Zheng L. Correlation study of expression levels of prostate-specific membrane antigen and prostate-specific antigen with Gleason score of prostate carcinoma. Zhonghua Zhong Liu Za Zhi. 2004;26:735–738
  67. Ross JS, Sheehan CE, Fisher HAG. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–6362
  68. Bander NH, Nanus DM, Milowsky MI. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol. 2003;30:667–676
  69. Bander NH. Technology Insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol. 2006;3:216–225
  70. David KA, Milowsky MI, Kostakoglu L, et al. Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. Clin Genitourin Cancer. 2006;4:249–256
  71. Milowsky MI, Nanus DM, Kostakoglu L. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22:2522–2531
  72. Small EJ: Monoclonal antibody therapy for prostate cancer: finally a reality? J Clin Oncol 22:2515-2516
  73. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591–4601
  74. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, et al. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005;11:7195s–7200s
  75. Singh D, Yi WS, Brasacchio RA, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases?. Int J Radiat Oncol Biol Phys. 2004;58:3–10
  76. D’Amico AV, Whittington R, Malkowicz SB. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7. Cancer. 2000;88:2110–2115
  77. Romer W, Reichel N, Vija HA, et al. Isotropic reconstruction of SPECT data using OSEM3D: correlation with CT. Acad Radiol. 2006;13:496–502
  78. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629–3634
  79. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–3198
  80. Gong MC, Chang SS, Sadelain M, et al. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev. 1999;18:483–490
  81. Ma D, Hopf CE, Malewicz AD, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res. 2006;12:2591–2596
  82. Ikegami S, Tadakuma T, Yamakami K, et al. Selective gene therapy for prostate cancer cells using liposomes conjugated with IgM type monoclonal antibody against prostate-specific membrane antigen. Human Cell. 2005;18:17–23
  83. Lee SJ, Zhang Y, Lee SD, et al. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol Ther. 2004;10:1051–1058
  84. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA. 2006;103:6315–6320

 Supported in part by Cytogen Corporation, Princeton, NJ.

PII: S0001-2998(06)00055-9

doi: 10.1053/j.semnuclmed.2006.07.002

Seminars in Nuclear Medicine
Volume 37, Issue 1 , Pages 17-28 , January 2007

Article Tools

* Image Usage & Resolution